肾癌患者术后接受重组人干扰素结合系统化个性护理的临床效果

Clinical Efficacy Study of Systemic Personalized Nursing Combined with Recombinant Human Interferon on Patients after Radical Nephrectomy

目的研究肾癌患者术后接受注射用重组人干扰素α-2b治疗结合系统化个性护理的效果。方法 2014年9月至2016年10月,便利抽样法选取在福建医科大学附属第二医院手术麻醉科接受根治术治疗的肾癌患者104例为研究对象。按治疗前后顺序将其分为观察组和对照组,每组52例。所有患者术后均接受重组人干扰素药物治疗,对照组患者接受常规护理,而观察组患者接受系统化个性护理。比较两组患者临床症状恢复时间、术后住院时间、焦虑自评量表(self-rating anxiety scale,SAS)和抑郁自评量表(self-rating depression scale,SDS)评分、护理满意度及不良反应发生率。结果观察组患者术后临床症状恢复状况及住院时间均优于对照组,差异均有统计学意义(均P<0.05);术后观察组SAS评分、SDS评分均优于对照组,差异均有统计学意义(P<0.05);观察组患者临床护理总满意率高于对照组,差异有统计学意义(P<0.05);观察组患者不良反应情况明显低于对照组,差异有统计学意义(P<0.05)。结论肾癌患者术后接受注射用重组人干扰素α-2b药物治疗时,给予系统化个性护理,能明显缩短临床症状恢复及住院时间,显著提高护理满意度,有效降低不良症状的发生,值得临床上推广应用。

Objective To study the clinical efficacy of systemic personalized nursing combined with recom- binant human interferon on patients after radical nephrectomy.Methods By convenience sampling, 104 pa- tients with renal cancer who treated radical surgery were selected and divided into observation group and control group according to the order of treatment, with 52 cases in each group. All patients were treated with recombinant human interferon, but control group received routine nursing, the observation group re- ceived systemic personalized nursing. The therapeutic effect was evaluated comprehensively by clinical symptom recovery time, postoperative hospital stay, self-rating anxiety scale （SAS） and self-rating de- pression scale （SDS） score, nursing satisfaction and incidence of adverse reaction. Results After treat- ment, clinical symptom recovery time and postoperative hospital stay time of observation group were sig- nificantly lower than those of the control group （all P〈0.05）. The SAS and SDS score of the observation group were significantly better than those of the control group （P〈0.05）. The nursing satisfaction of ob- servation group was significantly higher than those of the control group （P〈0.05）. The incidence rate of adverse reactions in observation group was significantly lower than those of the control group, the differ- ence was statistically significant （P〈0.05）.Conclusion Renal cancer patients treated with recombinant human interferon a-2b at the same time to give the systemic personalized nursing, which can significantly shorten clinical symptom recovery time and hospitalization stay time, improve the treatment effect and nursing satisfaction, reduce the incidence of adverse symptoms, it is worthy of clinical application.